BACKGROUND: Local drug delivery from polymer-coated stents has demonstrated efficacy for preventing in-stent restenosis; however, both the inflammatory effects of polymer coatings and concerns about late outcomes of drug-eluting stent use indicate the need to investigate innovative approaches, such as combining localized gene therapy with stent angioplasty. Thus, we investigated the hypothesis that adenoviral vectors (Ad) could be delivered from the bare-metal surfaces of stents with a synthetic complex for reversible vector binding. METHODS AND RESULTS: We synthesized the 3 components of a gene vector binding complex: (1) A polyallylamine bisphosphonate with latent thiol groups (PABT), (2) a polyethyleneimine (PEI) with pyridyldithio groups for amplification of attachment sites [PEI(PDT)], and (3) a bifunctional (amine- and thiol-reactive) cross-linker with a labile ester bond (HL). HL-modified Ad attached to PABT/PEI(PDT)-treated steel surfaces demonstrated both sustained release in vitro over 30 days and localized green fluorescent protein expression in rat arterial smooth muscle cell cultures, which were not sensitive to either inhibition by neutralizing anti-Ad antibodies or inactivation after storage at 37 degrees C. In rat carotid studies, deployment of steel stents configured with PABT/PEI(PDT)/HL-tethered adenoviral vectors demonstrated both site-specific arterial Ad(GFP) expression and adenovirus-luciferase transgene activity per optical imaging. Rat carotid stent delivery of adenovirus encoding inducible nitric oxide synthase resulted in significant inhibition of restenosis. CONCLUSIONS: Reversible immobilization of adenovirus vectors on the bare-metal surfaces of endovascular stents via a synthetic complex represents an efficient, tunable method for sustained release of gene vectors to the vasculature.
BACKGROUND: Local drug delivery from polymer-coated stents has demonstrated efficacy for preventing in-stent restenosis; however, both the inflammatory effects of polymer coatings and concerns about late outcomes of drug-eluting stent use indicate the need to investigate innovative approaches, such as combining localized gene therapy with stent angioplasty. Thus, we investigated the hypothesis that adenoviral vectors (Ad) could be delivered from the bare-metal surfaces of stents with a synthetic complex for reversible vector binding. METHODS AND RESULTS: We synthesized the 3 components of a gene vector binding complex: (1) A polyallylamine bisphosphonate with latent thiol groups (PABT), (2) a polyethyleneimine (PEI) with pyridyldithio groups for amplification of attachment sites [PEI(PDT)], and (3) a bifunctional (amine- and thiol-reactive) cross-linker with a labile ester bond (HL). HL-modified Ad attached to PABT/PEI(PDT)-treated steel surfaces demonstrated both sustained release in vitro over 30 days and localized green fluorescent protein expression in rat arterial smooth muscle cell cultures, which were not sensitive to either inhibition by neutralizing anti-Ad antibodies or inactivation after storage at 37 degrees C. In rat carotid studies, deployment of steel stents configured with PABT/PEI(PDT)/HL-tethered adenoviral vectors demonstrated both site-specific arterial Ad(GFP) expression and adenovirus-luciferase transgene activity per optical imaging. Rat carotid stent delivery of adenovirus encoding inducible nitric oxide synthase resulted in significant inhibition of restenosis. CONCLUSIONS: Reversible immobilization of adenovirus vectors on the bare-metal surfaces of endovascular stents via a synthetic complex represents an efficient, tunable method for sustained release of gene vectors to the vasculature.
Authors: J M Bergelson; J A Cunningham; G Droguett; E A Kurt-Jones; A Krithivas; J S Hong; M S Horwitz; R L Crowell; R W Finberg Journal: Science Date: 1997-02-28 Impact factor: 47.728
Authors: Thomas W Johnson; Yin Xiong Wu; Christian Herdeg; Andreas Baumbach; Andrew C Newby; Karl R Karsch; Martin Oberhoff Journal: Arterioscler Thromb Vasc Biol Date: 2005-01-27 Impact factor: 8.311
Authors: W J van der Giessen; A M Lincoff; R S Schwartz; H M van Beusekom; P W Serruys; D R Holmes; S G Ellis; E J Topol Journal: Circulation Date: 1996-10-01 Impact factor: 29.690
Authors: L L Shears; M R Kibbe; A D Murdock; T R Billiar; A Lizonova; I Kovesdi; S C Watkins; E Tzeng Journal: J Am Coll Surg Date: 1998-09 Impact factor: 6.113
Authors: Dirk H Walter; Manfred Cejna; Larry Diaz-Sandoval; Sean Willis; Laura Kirkwood; Peter W Stratford; Anne B Tietz; Rudolf Kirchmair; Marcy Silver; Cindy Curry; Andrea Wecker; Young-Sup Yoon; Regina Heidenreich; Allison Hanley; Marianne Kearney; Fermin O Tio; Patrik Kuenzler; Jeffrey M Isner; Douglas W Losordo Journal: Circulation Date: 2004-06-21 Impact factor: 29.690
Authors: Joshua B Slee; Ivan S Alferiev; Chandrasekaran Nagaswami; John W Weisel; Robert J Levy; Ilia Fishbein; Stanley J Stachelek Journal: Biomaterials Date: 2016-02-08 Impact factor: 12.479
Authors: Ilia Fishbein; Scott P Forbes; Richard F Adamo; Michael Chorny; Robert J Levy; Ivan S Alferiev Journal: J Vis Exp Date: 2014-08-12 Impact factor: 1.355
Authors: Vaishali V Inamdar; Emmett Fitzpatrick; Ivan Alferiev; Chandrasekaran Nagaswami; Lynn A Spruce; Hossein Fazelinia; George Bratinov; Steven H Seeholzer; Robert J Levy; Ilia Fishbein; Stanley J Stachelek Journal: Acta Biomater Date: 2020-01-11 Impact factor: 8.947
Authors: Scott P Forbes; Ivan S Alferiev; Michael Chorny; Richard F Adamo; Robert J Levy; Ilia Fishbein Journal: Atherosclerosis Date: 2013-06-29 Impact factor: 5.162
Authors: Ilia Fishbein; Scott P Forbes; Michael Chorny; Jeanne M Connolly; Richard F Adamo; Ricardo A Corrales; Ivan S Alferiev; Robert J Levy Journal: Biomaterials Date: 2013-06-15 Impact factor: 12.479
Authors: Ilia Fishbein; Tre Welch; David T Guerrero; Ivan S Alferiev; Richard F Adamo; Michael Chorny; Rohit K Gupte; Yanqing Tang; Robert J Levy Journal: Cardiovasc Pathol Date: 2016-08-20 Impact factor: 2.185